AsianFin -- Shares of French pharmaceutical giant Sanofi tumbled more than 9% on Thursday after late-stage trial results for its experimental inflammatory disease therapy, amlitelimab, fell short of Wall Street expectations.

Amlitelimab is being developed to treat atopic dermatitis, a severe form of eczema. Sanofi has positioned the drug as a potential complement or successor to its blockbuster treatment Dupixent, which also targets the condition. The disappointing data raised concerns over the drug’s commercial prospects and sent shares lower in Paris trading.